Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jupiter NeurosciencesJUNS -5.26% Forward PE Ratio is 1.50 as of Aug. 01, 2026. The stock has 5 warning signs investors should review. Among 354 Biotechnology companies, Jupiter Neurosciences ranks better than 93.22% on this metric.
Jupiter Neurosciences (NAS:JUNS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Jupiter Neurosciences Forward PE Ratio Related Terms
Jupiter Neurosciences Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Jupiter Neurosciences's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jupiter Neurosciences Forward PE Ratio Chart
Jupiter Neurosciences Annual Data
Trend
2025-12
Forward PE Ratio
19.00
Jupiter Neurosciences Quarterly Data
2025-09
2025-12
2026-03
Forward PE Ratio
26.50
19.00
5.77
JUNS vs CLGN, RNAZ, XBIO: Forward PE Ratio Comparison
For the Biotechnology subindustry, Jupiter Neurosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jupiter Neurosciences Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Jupiter Neurosciences's Forward PE Ratio falls into.
Jupiter Neurosciences Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Jupiter Neurosciences (JUNS) has a Forward PE Ratio of 1.50 as of Aug. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Jupiter Neurosciences and its competitors. According to the industry distribution chart, Jupiter Neurosciences ranks #24 out of 354 companies in the Biotechnology industry, placing it in the top 6.8%.
Is Jupiter Neurosciences' Forward PE Ratio too high?
Jupiter Neurosciences' current Forward PE Ratio is 1.50. The Biotechnology industry median Forward PE Ratio is 22.53. Jupiter Neurosciences' value of 1.50 is 93.3% below this industry median. Based on the distribution chart, Jupiter Neurosciences ranks #24 out of 354 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Jupiter Neurosciences' Forward PE Ratio compare to CLGN and RNAZ?
According to the Biotechnology industry distribution chart, Jupiter Neurosciences ranks #24 out of 354 companies for Forward PE Ratio. This places Jupiter Neurosciences in the top 7% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 22.53. Jupiter Neurosciences' value of 1.50 is 93.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.53, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jupiter Neurosciences's current Forward PE Ratio of 1.50 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Jupiter Neurosciences and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jupiter Neurosciences's current Forward PE Ratio is 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Forward PE Ratio of 1.50. The current Forward PE Ratio is 1.50 and 93.3% below the Biotechnology industry median of 22.53. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Forward PE Ratio is 1.50 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUNS has been successfully added to your 
